Nanomedicine for prion disease treatment

References

• Supattapone S, Nguyen HO, Cohen FE, Prusiner SB, Scott MR. Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 1999; 96:14529 - 34; http://dx.doi.org/10.1073/pnas.96.25.14529; PMID: 10588739
   PubMed Web of Science ®Google Scholar
• Klajnert B, Appelhans D, Komber H, Morgner N, Schwarz S, Richter S, et al. The influence of densely organized maltose shells on the biological properties of poly(propyleneimine) dendrimers: new effects dependent on hydrogen bonding. Chemistry 2008; 14:7030 - 41; http://dx.doi.org/10.1002/chem.200800342; PMID: 18576443
   PubMed Web of Science ®Google Scholar
• Fischer M, Appelhans D, Schwarz S, Klajnert B, Bryszewska M, Voit B, et al. Influence of surface functionality of poly(propyleneimine) dendrimers on protease resistance and propagation of the scrapie prion protein. Biomacromolecules 2010; 11:1314 - 25; http://dx.doi.org/10.1021/bm100101s; PMID: 20405854
   PubMed Web of Science ®Google Scholar
• Supattapone S, Wille H, Uyechi L, Safar J, Tremblay P, Szoka FC, et al. Branched polyamines cure prion-infected neuroblastoma cells. J Virol 2001; 75:3453 - 61; http://dx.doi.org/10.1128/JVI.75.7.3453-3461.2001; PMID: 11238871
   PubMed Web of Science ®Google Scholar
• Solassol J, Crozet C, Perrier V, Leclaire J, Béranger F, Caminade AM, et al. Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol 2004; 85:1791 - 9; http://dx.doi.org/10.1099/vir.0.19726-0; PMID: 15166465
   PubMed Web of Science ®Google Scholar
• Sebestik J, Niederhafner P, Jezek J. Peptide and glycopeptide dendrimers and analogous dendrimeric structures and their biomedical applications. Amino Acids 2011; 40:301 - 70; http://dx.doi.org/10.1007/s00726-010-0707-z; PMID: 21058024
   PubMed Web of Science ®Google Scholar
• McCarthy JM, Rasines Moreno B, Filippini D, Komber H, Maly M, Cernescu M, et al. Influence of surface groups on poly(propyleneimine) dendrimers antiprion activity. Biomacromolecules 2013; 14:27 - 37; http://dx.doi.org/10.1021/bm301165u; PMID: 23234313
   PubMed Web of Science ®Google Scholar
• Ciolkowski M, Pałecz B, Appelhans D, Voit B, Klajnert B, Bryszewska M. The influence of maltose modified poly(propyleneimine) dendrimers on hen egg white lysozyme structure and thermal stability. Colloids Surf B Biointerfaces 2012; 95:103 - 8; http://dx.doi.org/10.1016/j.colsurfb.2012.02.021; PMID: 22410344
   PubMed Web of Science ®Google Scholar
• Boas U, Christensen JB, Heegaard PMH. Dendrimers in medicine and biotechnology: new molecular tools. Cambridge, U.K.: Royal Society of Chemistry, 2006.
   Google Scholar
• McCarthy JM, Franke M, Resenberger UK, Waldron S, Simpson JC, Tatzelt J, et al. Anti-prion drug mPPIg5 inhibits PrP(C) conversion to PrP(Sc). PLoS One 2013; 8:e55282; http://dx.doi.org/10.1371/journal.pone.0055282; PMID: 23383136
   PubMedGoogle Scholar
• Klöhn PC, Stoltze L, Flechsig E, Enari M, Weissmann C. A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci U S A 2003; 100:11666 - 71; http://dx.doi.org/10.1073/pnas.1834432100; PMID: 14504404
   PubMed Web of Science ®Google Scholar
• Pless DD, Wellner RB. In vitro fusion of endocytic vesicles: effects of reagents that alter endosomal pH. J Cell Biochem 1996; 62:27 - 39; http://dx.doi.org/10.1002/(SICI)1097-4644(199607)62:1<27::AID-JCB4>3.0.CO;2-3; PMID: 8836873
   PubMed Web of Science ®Google Scholar
• McCarthy JM, Rasines B, Appelhans D, Rogers M. Differentiating prion strains using dendrimers. Adv Healthc Mater 2012; 1:768 - 72; http://dx.doi.org/10.1002/adhm.201200151; PMID: 23184829
   PubMed Web of Science ®Google Scholar
• Lim YB, Mays CE, Kim Y, Titlow WB, Ryou C. The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity. Biomaterials 2010; 31:2025 - 33; http://dx.doi.org/10.1016/j.biomaterials.2009.11.085; PMID: 20022103
   PubMed Web of Science ®Google Scholar
• Caughey B, Raymond GJ, Ernst D, Race RE. N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease(s): implications regarding the site of conversion of PrP to the protease-resistant state. J Virol 1991; 65:6597 - 603; PMID: 1682507
   PubMed Web of Science ®Google Scholar
• Deleault NR, Kascsak R, Geoghegan JC, Supattapone S. Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein in vitro. Biochemistry 2010; 49:3928 - 34; http://dx.doi.org/10.1021/bi100370b; PMID: 20377181
   PubMed Web of Science ®Google Scholar
• Heegaard PMH, Pedersen HG, Flink J, Boas U. Amyloid aggregates of the prion peptide PrP106-126 are destabilised by oxidation and by the action of dendrimers. FEBS Lett 2004; 577:127 - 33; http://dx.doi.org/10.1016/j.febslet.2004.09.073; PMID: 15527773
   PubMed Web of Science ®Google Scholar
• Klajnert B, Cortijo-Arellano M, Cladera J, Bryszewska M. Influence of dendrimer’s structure on its activity against amyloid fibril formation. Biochem Biophys Res Commun 2006; 345:21 - 8; http://dx.doi.org/10.1016/j.bbrc.2006.04.041; PMID: 16674918
   PubMed Web of Science ®Google Scholar
• Klajnert B, Cortijo-Arellano M, Cladera J, Majoral JP, Caminade AM, Bryszewska M. Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185-208. Biochem Biophys Res Commun 2007; 364:20 - 5; http://dx.doi.org/10.1016/j.bbrc.2007.09.083; PMID: 17927954
   PubMed Web of Science ®Google Scholar
• Colby DW, Prusiner SB. Prions. Cold Spring Harb Perspect Biol 2011; 3:a006833; http://dx.doi.org/10.1101/cshperspect.a006833; PMID: 21421910
   PubMed Web of Science ®Google Scholar
• Resenberger UK, Harmeier A, Woerner AC, Goodman JL, Müller V, Krishnan R, et al. The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication. EMBO J 2011; 30:2057 - 70; http://dx.doi.org/10.1038/emboj.2011.86; PMID: 21441896
   PubMed Web of Science ®Google Scholar
• Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, et al. Alzheimer’s disease brain-derived amyloid-β-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci 2011; 31:7259 - 63; http://dx.doi.org/10.1523/JNEUROSCI.6500-10.2011; PMID: 21593310
   PubMed Web of Science ®Google Scholar
• Soto C. Prion hypothesis: the end of the controversy?. Trends Biochem Sci 2011; 36:151 - 8; http://dx.doi.org/10.1016/j.tibs.2010.11.001; PMID: 21130657
   PubMed Web of Science ®Google Scholar
• Lane AR, Stanley CJ, Wilson SM. Binding of pathological forms of prion proteins. MICROSENS BIOPHAGE LTD (GB), 2010.
   Google Scholar
• Klajnert B, Cladera J, Bryszewska M. Molecular interactions of dendrimers with amyloid peptides: pH dependence. Biomacromolecules 2006; 7:2186 - 91; http://dx.doi.org/10.1021/bm060229s; PMID: 16827586
   PubMed Web of Science ®Google Scholar
• Klajnert B, Cangiotti M, Calici S, Majoral JP, Caminade AM, Cladera J, et al. EPR study of the interactions between dendrimers and peptides involved in Alzheimer’s and prion diseases. Macromol Biosci 2007; 7:1065 - 74; http://dx.doi.org/10.1002/mabi.200700049; PMID: 17654761
   PubMed Web of Science ®Google Scholar
• Wasiak T, Ionov M, Nieznanski K, Nieznanska H, Klementieva O, Granell M, et al. Phosphorus Dendrimers Affect Alzheimer’s (Aβ1–28) Peptide and MAP-Tau Protein Aggregation. Mol Pharm 2011; 9:458 - 69; http://dx.doi.org/10.1021/mp2005627
   Web of Science ®Google Scholar
• Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci 2001; 24:1121 - 59; http://dx.doi.org/10.1146/annurev.neuro.24.1.1121; PMID: 11520930
   PubMed Web of Science ®Google Scholar
• Janaszewska A, Ziemba B, Ciepluch K, Appelhans D, Voit B, Klajnert B, et al. The biodistribution of maltotriose modified poly (propyleneimine)(PPI) dendrimers conjugated with fluorescein—proofs of crossing blood–brain–barrier. New J Chem 2012; 36:350 - 3; http://dx.doi.org/10.1039/c1nj20444k
   Web of Science ®Google Scholar